Products for Research Use Only

TNG260

CAT: 0804-HY-153358-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153358-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TNG260 is a selective, orally effective inhibitor of HDAC1 and CoREST complex, with a 10-fold selectivity for HDAC1 over HDAC3 and a 500-fold selectivity for CoREST complex over NuRD and Sin3 complex. TNG260 reshapes the tumor immune microenvironment, reduces immunosuppressive neutrophil infiltration, promotes effector T cell recruitment, and reverses anti-PD-1 resistance caused by STK11 deficiency by inhibiting the activity of the CoREST-HDAC1 complex. TNG260 induces durable tumor regression in combination with α-PD1 in MC38 tumor-bearing mice with STK11 mutations, and has lower toxicity to bone marrow cells than non-selective HDAC inhibitors[1].
CAS Number
2935964-98-8
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tng260.html
Purity
99.33
Solubility
DMSO : 2.22 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC1=CC=C(C2=CC=C(F)C=C2)C=C1NC(C3=CC=C([S@](=O)(C)=N)C=C3)=O
Molecular Formula
C20H18FN3O2S
Molecular Weight
383.44
References & Citations
[1]Ahronian L, et al. TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11[J]. J Immunother, 2022, 10 (2) : A1-A1595.|[2]Patel Ayushi, et al. TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy. Cancer Research 84.6_Supplement (2024) : 3916-3916.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HDAC1; HDAC3

Popular Products